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Key Points
 Significant changes in anesthetic management for optimizing cerebral perfusion have
occurred over the past 5 to 10 years. Perhaps the most important of these changes has
been a reinterpretation of older autoregulation studies that have resulted in raising the
lower limit of autoregulation to approximately 70 mm Hg to 80 mm Hg, and not the
previously used 60 mm Hg.
 Tremendous variability in the lower limits of autoregulation exists among individuals.
Using a percentage reduction below baseline blood pressure as a lower limit may
result in better optimization of cerebral perfusion than using absolute blood pressure
values.
 Other changes in practice for the general anesthesiologist include correcting blood
pressure for height differences between the site of blood pressure measurement and
the brain, particularly in the sitting position, to account for the hydrostatic gradient.
Rare cases of severe brain damage have been reported that may be related to hy-
poperfusion in the beach chair position.
 Multiple physiologic and drug interactions that affect cerebral perfusion occur during
every general anesthestic, and understanding the best way to optimize cerebral blood
flow may potentially improve outcomes. Newer research on flow-metabolism coupling
points to regional control of cerebral blood flow by the neurovascular unit, with glial
cells playing a central role.Disclosures: Dr Greene and Dr Lee report no financial disclosures.
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Defining the parameters that affect cerebral perfusion and understanding the
pathophysiologic conditions that result in a supply and demand mismatch is
of paramount concern for anesthesiologists. Stroke is one of the most devas-
tating perioperative complications, and can occur with an incidence of 0.1%
to 1.0% in patients undergoing noncardiac, non-neurological procedures, using
national database statistics [1]. It is difficult to estimate what percentage of these
perioperative strokes are related to embolic phenomena versus hypoperfusion,
but hypoperfusion was strongly implicated as a causative factor in the multi-
center randomized controlled trial Perioperative Ischemic Evaluation Study
(POISE), in which patients receiving perioperative beta blockade had a twofold
increased risk of stroke compared with patients who received placebo [2].
Retrospective single-institution studies have also found a significant relation-
ship between perioperative stroke and intraoperative hypotension [3]. In
contrast, a recent review of the literature noted that hypoperfusion was causa-
tive in only 6.6% of the 301 strokes identified [4]; yet, several studies have sug-
gested that hypoperfusion may exacerbate the effect of microemboli. The
indirect evidence suggests that ‘‘low’’ mean arterial pressure (MAP) may
increase the risk of a perioperative stroke in certain high-risk individuals, but
defining ‘‘low’’ for all patients and all procedures is problematic.
The goal of this article was to enhance the reader’s understanding about
factors that affect cerebral blood flow (CBF), and to reexamine some misper-
ceptions from earlier clinical studies on cerebral autoregulation and their
impact on clinical practice. Rarer neurologic complications, such as ischemic
optic neuropathy related to the prone and steep Trendelenburg positions,
and severe brain damage in the sitting position, that highlight the potentially
deleterious impact of patient position on cerebral perfusion are also discussed.
FUNDAMENTALS OF CBF
Humans have long been interested in cerebral perfusion and the brain as far
back as 2800 BC, but it was not until the mid-1900s that the first techniques
to measure CBF were developed by Kety and Schmidt (Fig. 1) [5–7]. We
now have at least 18 different methods for measuring CBF, with newer tools
of analysis, such as functional magnetic resonance imaging and positron emis-
sion computed tomography, that can demonstrate 3-dimensional images of
CBF to a resolution of less than 1 cm [6]. Widespread use of these newer tech-
niques should improve our understanding of cerebral perfusion to better guide
our clinical practice.
Inherent to understanding perfusion of the brain is first understanding the
immense metabolic requirement of the brain. The brain makes up only 2%
of the body weight, but receives as much as 15% to 20% of the cardiac output,
approximately 50 to 60 mL/100 g brain tissue/min, or 750 to 1000 mL/min in
an adult. It consumes as much as 20% of the total oxygen requirement at
resting conditions at 3.3 mL/100 g brain tissue/min [5,6]. Of the oxygen
used, 40% is devoted to what is known as basal metabolism: homeostasis of
Fig. 1. Timeline of important milestones in the history of cerebral perfusion research. Data
from Refs. [5–7].
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ion gradients, and providing substrate for the central nervous system to
communicate (ie, neurotransmitters, polypeptides, complex proteins). The
other 60% is necessary for what is known as activation or functional metabo-
lism: the energy required to support electrophysiologic function and to allow
the neurons of the brain to communicate [5,6]. Because of its high metabolic
activity and relatively low energy storage capacity, the brain is especially
vulnerable to interruption of oxygen and substrate delivery.Circle of Willis
In its most simple description, the circle of Willis is a continuous arterial circle
that forms at the base of the brain by interconnections between branches of the
left and right internal carotid arteries and the vertebrobasilar system. This
circle is made because of formation of an anterior communicating artery that
connects the left and right internal carotid systems between both anterior cere-
bral arteries, and the formation of posterior communicating arteries bilaterally
that connect the carotid systems to the vertebrobasilar system between the
middle cerebral arteries and the posterior cerebral arteries. Willis seemed to
put it best after he made his anatomic discovery when he wrote ‘‘if by chance
one or two should be stopt, there might easily be found another passage instead
of them’’ [7]. The circle receives blood from 4 distinct sources that directly
come from branches of the aorta with both internal carotid arteries being fed
via the common carotid artery and both vertebral arteries being fed via the
subclavian arteries. It should be noted that there is significant variance in the
human population, with some studies suggesting that fewer than half of the
population possess a complete circle of Willis.Control of CBF
There are several different mechanisms controlling CBF. The brain has adapt-
ed the ability to match CBF with metabolic rate through a variety of physio-
logic mechanisms, better known as flow-metabolism coupling. This coupling
can occur regionally and is governed by several mechanisms that serve as
the basis of how the brain is able to meet its unique demands. It is useful to
separate these mechanisms into separate components with the understanding
that they are still interrelated and can work either in concert or in opposition.Chemical/metabolic control
The neurovascular unit. Current research indicates that the control of flow-
metabolism coupling is primarily mediated through neurovascular units con-
sisting of cerebral blood vessels, glial cells whose endfeet wrap around the
vessels, and perivascular nerve fibers innervating the cerebral vessels and the
glial cells (Box 1). The glial cells appear able to ‘‘sense’’ increased neuronal
activity and release diffusible vasodilatory substances from the endfeet, thereby
affecting CBF. More specifically, increased neuronal activity results in an
increase in glial intracellular calcium, causing a release of ATP and glutamate
[8]. ATP is involved in recruiting adjacent glial cells to respond as a unit via
Box 1: Control of CBF
Control of CBF is centered around the neurovascular unit, which consists of the
following:
 Perivascular nerve fibers innervating glial cells and blood vessels
 Glial cells with endfeet that wrap around cerebral vessels
 Cerebral vessels
Diffusible substances are secreted by the nerve fibers and glial cells, which affect CBF and
increase connectivity of the neurovascular unit. The vascular endothelium also contributes to
control of CBF. Glutamate affects both metabolism and CBF.
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ulate production of nitric oxide (NO), which is a cerebral vasodilator and
thought to be involved in the regulation of flow-metabolism coupling. Gluta-
mate also activates glial cells via metabotropic glutamate receptors with subse-
quent calcium signaling and arachadonic acid formation. Arachadonic acid, or
its lipid derivatives, serve as vasodilatory or vasoconstrictor substances
released by the glial endfeet surrounding the cerebral blood vessels. NO,
Kþ, Hþ, brain metabolites, such as adenosine and lactate, and O2 influence
the direction of vascular tone [9]. Kþ and Hþ ions are produced by synaptic
transmission, and increases in their concentrations stimulate cerebral vasodila-
tion. Glutamate uptake by glial cells generates sodium waves that subsequently
increase glucose uptake and metabolism. The increased lactate production
from this metabolism is used by neurons as an energy substrate [8]. Glutamate
increases connectivity of glial cells with neurons and capillaries (the neurovas-
cular unit) as it affects both metabolism and CBF. The glial cells (astrocytes)
play a vital role in local flow–metabolism coupling.
The perivascular nerve endings of cerebral vessels are also thought to be
involved in flow-metabolism coupling via release of neurotransmitters, such as
norepinephrine, acetylcholine, substance P, somatostatin, cholecystokinin, vaso-
active intestinal peptide, calcitonin gene-related peptide, epoxyeicosatrienoic acids
(EETs), and others [10]. EETs are arachidonic acid metabolites, which are potent
cerebral vasodilators and are also produced by astrocytes and the vascular endo-
thelium. The source of innervation for this cerebral microvasculature (or
‘‘intrinsic innervation’’) is unknown in humans, but is thought to arise from the
nucleus basalis, locus coeruleus, and raphe nucleus in animals [6]. The extrinsic
innervation for flow-metabolism coupling is discussed later in this article.
Carbon dioxide. CO2, the main by-product of aerobic respiration, is a potent cere-
bral vasodilator and provides a very basic model of regulation by shifting blood
toward more metabolically active tissues. A linear relationship exists between
CBF and CO2 tension throughout normal physiologic values of CO2 (20–75
mm Hg), with an approximate 2% to 6% change in CBF per mm Hg CO2
[6,11,12]. The effect of changes in CO2 on CBF depends on the underlying
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vasodilation (and vasoconstriction) beyond which the vessel cannot further alter
its diameter. For example, profound hypotension can greatly diminish CO2 reac-
tivity because the cerebral vessels are maximally vasodilated. Similarly, hyper-
capnia can impede autoregulation for the same reasons.
The mechanism of CO2 reactivity is related to changes in the pH of the extra-
cellular fluid surrounding the brain. Low-pH solutions topically applied to the
brain surface cause vasodilation, whereas high-pH solutions cause vasoconstric-
tion. CO2, unlike Hþ ions, readily diffuses across the blood brain barrier and
cerebral endothelium [6]. Consequently, CO2 changes have a relatively quick
effect on CBF, but metabolic acidosis has little immediate effect on CBF.
Because the cerebrospinal fluid actively eliminates bicarbonate with prolonged
hyperventilation and normalizes its pH, effects on CBF typically revert to base-
line within approximately 6 hours, even though the arterial partial pressure of
CO2 (PaCO2) may remain low. Thus, acute correction of PaCO2 after prolonged
hyperventilation can lead to pronounced increases in CBF, which may have
deleterious effects on patients with raised intracranial pressure (ICP) [6].
The change in vascular tone caused by CO2 is partially mediated by NO, as
inhibitors of NO synthase will diminish the vasodilatory response to hyper-
capnia. NO modulation of cerebrovascular tone occurs through combined acti-
vation of ATP-sensitive and calcium-activated potassium channels in animal
studies [13]. Indomethacin, an inhibitor of cyclooxygenase and prostaglandin
formation, will partially inhibit the vasodilatory response to increasing CO2
concentrations in humans. Experimental studies in animals show that applica-
tion of prostaglandin E2 (PGE2) after indomethacin administration will restore
the cerebrovascular reactivity to baseline, as PGE2 is thought to stimulate
production of endothelial NO synthase [14]. Studying these mechanisms at
this level of complexity has been difficult, as they have been shown to differ
depending on the animal studied.
PaO2, arterial O2 content, and rheology. Oxygen (O2), also exhibits regulatory
capacity, asCBF increaseswhenO2 levels start todropbelow60mmHg inhumans
[15]. Early studies in normocapnic rats showed that CBF significantly increased at
PaO2 levels as high as 85mmHg, but that marked increases up to 500%of baseline
CBFoccurredwithin 1 to 2minutes at aPaO2of 25mmHg [16].NOsynthase inhib-
itors given to humans partially blocked this response, suggesting that it is partially
regulated by NO [17]. Chemoreceptors in the periphery and neuraxis, and hyper-
polarization of vascular smooth muscle via ATP-dependent potassium channels,
may also contribute to hypoxia-induced vasodilation [6].
Hypoxemia increases CBF to a greater degree than hemodilution, at the
same arterial O2 content (CaO2) [18]. Hemodilution has been well documented
in animal and human studies to increase CBF and raise the lower limit of au-
toregulation (LLA) [18,19]. Both the decreased viscosity with improved
rheology, and reduced CaO2 are responsible for the increase in CBF with
hemodilution, based on studies in animals [20]. Although NO is involved in
103CEREBRAL PERFUSION AND AUTOREGULATIONcerebral vasodilation with reduced CaO2 from hypoxemia, it does not appear
to contribute to increased CBF with reduced viscosity [18].
Temperature. Temperature-induced changes in CBF are a reflection of changes in
the cerebral metabolic rate of O2 (CMRO2). As a patient’s temperature drops,
there is a corresponding drop in CMRO2 from both basal and functional metab-
olism, estimated to be approximately 7% for each 1C between 37C and 27C
[5]. Isoelectric electroencephalogram (EEG) occurs at temperatures of 18 to
20C. Pharmacologic suppression, which only affects functional metabolism, is
synergistic with hypothermic suppression until EEG silence. At that point,
CMRO2 can be reduced only by further drops in temperature [6]. Numerous
smaller studies have documented the improved survival and outcomes using
mild to moderate hypothermia in traumatic brain injury (TBI) and other patho-
logic states, and the deleterious effects of hyperthermia. Larger randomized
controlled trials of hypothermia in traumatic brain injury and during clipping
of cerebral aneursyms have not demonstrated a beneficial effect for all patients
[21,22]. Hypothermia seems to be neuroprotective during vulnerable periods
of cerebral ischemia in successfully resuscitated cardiac arrest patients [23].
One of the few studies in humans with hyperthermia and controlled ventila-
tion showed that increasing temperatures to 41.8C with propofol anesthesia
decreased O2 extraction by 1.6-fold and increased middle cerebral artery blood
flow velocity by 1.5-fold, with partial impairment of autoregulation [24]. It was
suggested that the decreased O2 extraction was a consequence of a similar
increase in CBF, and that CMRO2 may actually have been stable. In animals,
CMRO2 increases up to 42C, and then falls to baseline values or lower at
43C, presumably because of metabolic dysfunction and impending cell death.
In contrast to anesthetized subjects with controlled ventilation, research in
awake, spontaneously ventilating humans and animals revealed that CBF
decreased with hyperthermia, largely because of an associated increase in venti-
lation and reduced PaCO2 (Box 2) [25].Neurogenic control
In addition to the extensive network of perivascular nerve endings associated
with the neurovascular unit discussed previously, neurogenic control of CBFBox 2: Physiologic parameters affecting CBF
 Carbon dioxide
 PaO2/arterial O2 content
 Temperature
 Viscosity/rheology
 Sympathetic/Parasympathetic stimulation
 Myogenic control/autoregulation
Anemia increases CBF by its effect on viscosity/rheology and arterial O2 content.
104 GREENE & LEEis also mediated via sympathetic (adrenergic), parasympathetic (cholinergic),
and sensory neurons that innervate vessels outside of the brain tissue, some-
times referred to as the ‘‘extrinsic innervation’’ [26]. The extrinsic system of
neurogenic control of CBF is thought to exert its most pronounced effect on
the large cerebral arteries. The sympathetic nervous system associated with
the superior cervical ganglion influences vascular tone to maintain blood pres-
sure below the upper limit of autoregulation [27]. Sympathetic stimulation can
alter the autoregulatory curve and push it to the right, possibly providing
a protective effect during periods of acute hypertension [28,29]. Intense stimu-
lation of the sympathetic nervous system has been shown to cause a significant
decrease in CBF, whereas local blockade of the sympathetic nervous system
can provide a significant increase in CBF [28,30]. In a study using baboons,
in which autoregulation was intact to 35% of baseline blood pressure when
hypotension was drug induced, autoregulation was intact to only 65% of base-
line blood pressure when hypotension was induced by controlled hemorrhage,
suggesting that activation of the sympathetic nervous system during hemor-
rhage contributed to a higher LLA [31]. The role of lower cardiac output in
this scenario was not elucidated, but numerous studies suggest that acute hypo-
volemia may narrow the range of autoregulatory capacity and raise the LLA
via activation of the sympathetic nervous system.
The parasympathetic nervous system is associated with the sphenopalatine
and otic ganglia and is more functional during disease or injury states, such as
Alzheimer disease, with decreased cholinergic innervation [26]. However, both
the cholinergic and adrenergic nerves are thought to be involved in exercise-
induced changes in CBF and metabolism. Sensory neurons work through the
trigeminal ganglion and are important for pain sensation [26]. The discovery
of trigeminal neurons in mediating migraine pain via the vasodilator, calcitonin
gene-related peptide (CGRP), has led to the development of triptan drugs that
inhibit release of CGRP presynaptically and cause cerebral vasoconstriction.Myogenic control/autoregulation
In the healthy resting human, CBF is kept constant over a wide range of cerebral
perfusion pressures (CPP) via cerebral vasoconstriction and vasodilation. This
concept is known as autoregulation and seems to exist in humans, as well as in other
vertebrates. It is a process whereby changes in CPP cause changes in cerebrovas-
cular resistance to maintain a constant CBF. Cerebral autoregulation protects the
brain from hypoxia at low CPP, and against hyperemia, capillary leakage, and
vasogenic edema at high CPP. As the cerebral vessels have limits to how wide
they can dilate and how small they can constrict, there are limits to this autoregu-
latory capacity, and if exceeded, blood flow becomes pressure passive and is subject
to changes in systemic bloodpressure.TheLLA is theCPPwhen there ismaximal
cerebral vasodilation. The upper limit of autoregulation (ULA) is the CPPwhere
there is maximal cerebral vasoconstriction (Fig. 2). Autoregulatory ranges vary
greatly among individuals andwithin an individual depending onother influences
on vascular tone (eg, PaCO2, hemoglobin concentration, anesthetic agents). Older
Fig. 2. Pharmacology of CBF. Drugs and physiologic parameters that affect CBF and autoregulation *, **
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106 GREENE & LEEtexts have cited limits of autoregulation in healthy patients under normal physio-
logic conditions at a CPP of 50 mmHg (approximate MAP of 60 mmHg) at the
LLA and 140 mmHg (approximate MAP 150 mmHg) at the ULA. Reinterpret-
ing these older studies for clinical translation has led to a revision of the LLA to
aMAPof 70mmHg inhealthy adults, (see sectionLowerLimit ofAutoregulation
that follows) [6].
The process by which autoregulation occurs is unknown but is relatively
slow, taking approximately 2 or more minutes for CBF to adjust to baseline
values after an acute drop in MAP. Autonomic innervations of the central
nervous system and NO may have contributory roles to the mechanism of
autoregulation [32]. Increases in transmural pressure are known to induce an
endothelium-derived factor that induces smooth muscle depolarization. This
depolarization causes a conformational change in the actin-myosin complex
of the smooth muscle cells within seconds and results in vasoconstriction.
Recent research has detected mechanoreceptors within the smooth muscle cells
themselves. Depolarization of these nonselective mechanosensitive ion chan-
nels results in an influx of Caþþ and smooth muscle constriction. Increased
flow velocity exerts increased shear stress and can cause vasoconstriction inde-
pendent of transmural pressure [26].
LOWER LIMIT OF AUTOREGULATION
Historical interpretation of the LLA for cerebral ischemia
The LLA commonly refers to the MAP (or CPP) on the CBF versus MAP
(or CPP) autoregulatory curve in which the cerebral blood vessels are maximally
dilated, and in which CBF becomes pressure passive if MAP (or CPP) is further
lowered (Fig. 3). In the past, the LLA has erroneously been thought of as an abso-
lute number for all patients. Instead, it varies among and within individuals, and
depends on the state ofmultiple other physiologic parameters and pharmacologic
agents that may influence cerebral sympathetic tone and limit the extent of autor-
egulatory capacity. It has received great attention because of the implications for
blood pressure management under anesthesia in normal and diseased states.
Because intact neurologic function cannot be assessed, even with today’s best
technology, under moderate to deep sedation or general anesthesia, anesthesiol-
ogists have always been interested in defining the lower limit of ‘‘safe’’ blood pres-
sure whereby adequate cerebral perfusion is ensured if blood pressure is
maintained above this lower limit. Although one could always keep the MAP,
no lower than baseline values to ensure adequate CPP, this practice may have
the unintended consequences of increased bleeding in some procedures, and
could promote harmful side effects of increased blood transfusion, or other fluid
or vasoactive medication administration.
Blood pressures lower than a predetermined LLA do not necessarily result in
immediate and irreparable brain damage. The duration and extent of the
decrease inCPP below the LLAare important, with less dramatic decreases being
tolerated for longer duration. Awake healthy subjects developed symptoms of
cerebral ischemia at CBF of 24 to 38 mL/100 g/min [33]. Although most studies
Fig. 3. Autoregulation curve. The cerebral vasculature maintains a stable CBF over a wide
range of CPP (typically CPP 60–140 or MAP 70–150 mm Hg). The lower end of the autore-
gulatory range is the LLA, where there is maximal cerebral vasodilation. The ULA is when there
is maximal cerebral vasoconstriction. The area between the baseline MAP and the LLA is
known as the lower limit reserve (LLR). Symptoms and signs (EEG slowing) of cerebral ischemia
occur at approximately 24 to 38 mL/100 g/min CBF and neuronal damage is still reversible.
Functional metabolism ceases between 15 and 6 mL/100 g/min with an isoelectric EEG, and
neurons will eventually die. Destruction of cell integrity occurs at approximately CBF <6 mL/
100 g/min and rapid cell death ensues. The lower the CBF at ischemic levels, the shorter
the duration allowable before irreversible neuronal damage. The dashed-dotted line represents
the range of LLAs from 11 autoregulation studies in awake humans. (Data from Drummond JC.
The lower limit of autoregulation: time to revise our thinking? Anesthesiology
1997;86(6):1431–3.)
107CEREBRAL PERFUSION AND AUTOREGULATIONin anesthetized humans and primates report that EEG or evoked potential
changes do not occur until CBF declines to approximately 20 mL/100 g/min
[34,35], preexisting neuronal injury may raise that threshold to as high as
39mL/100 g/min [36]. Other factors thatmay reduceO2 delivery, such as anemia
or low PaO2, or increase in CMRO2, may raise the CBF threshold in which
ischemia develops. In anesthetized primates at a CBF of 15 mL/100 g/min, func-
tional metabolism ceases as demonstrated by an isoelectric EEG, and below
6 mL/100 g/min, cell integrity is potentially irreversibly threatened [37].
Although irreversible brain damage will not occur if a patient’s MAP briefly
drops below his or her LLA, keeping the MAP above the LLA should provide
some margin for error, assuming other physiologic conditions are normal.
Determination of the LLA for a population is problematic. As noted previ-
ously, careful reconsideration of the early studies on autoregulation has resulted
in a revised recommendation to maintain MAP at 70 mmHg or higher in major
anesthesia texts [6]. This number was derived from the mean LLA of the studies
108 GREENE & LEEexamined by Drummond in his brief review [38]. It has always been standard
practice in articles to list the mean values with the standard deviations (SDs).
As an unintended consequence of this practice, the focus of the data lies with
the mean values, which when used as a cutoff point will not encompass a large
proportion of the subjects and their variability. Using the mean value plus 1
SD should encompass 68.2% of the values in a normally distributed bell-
shaped curve; the mean value plus 2 SDs, 95.9%; and the mean value plus
3 SDs, 99.7%. Drummond attempted to rectify this misconstrued extrapolation
of autoregulation studies by denoting the ranges of the LLAs within multiple au-
toregulation studies in awake patients, instead of using only the mean LLAs
(Box 3) [38]. The range of mean LLAs was 57 to 91 mm Hg, with 5 of these
7 studies obtaining a mean LLA of 70 mmHg or higher. Moreover, if the ranges
of LLAs within studies were examined, every study had the upper range of LLA
above 70 mm Hg, and 4 of the 7 studies had the upper range of LLA at 100 mm
Hg or higher. Notably, these autoregulation studies were performed in awake
individuals, and presumably CMRO2 will be reduced in patients under general
anesthesia. Further, many of our anesthetic agents are cerebral vasodilators and
may provide another ‘‘buffer’’ to preventing inadequate cerebral perfusion; yet,
unfavorable physiologic conditions, which lower CBF or raise the LLA, such as
hypocapnia and anemia, may also be present, whichmay decrease themargin for
‘‘error’’ or harm on lowering the blood pressure.Defining LLA as a percentage reduction of MAP below baseline
Drummond [38] advocated revisiting what we considered a ‘‘safe’’ LLA by using
percentage reductions from baseline resting MAPs as a way to address the
extreme interpatient variability in absolute LLA values. This practice is standard
management in neuroanesthesia. Strandgaard [39] demonstrated in 1976 that
awake normotensive subjects’ mean LLA was approximately 74%  12% of
baseline, or a 26% 12% reduction from baseline MAP. In patients with uncon-
trolled hypertension, the LLA was 79%  10% of baseline MAP, or a 21% 
10% reduction from baseline MAP (see Box 3). Ischemic symptoms developed
in both groups at approximately 55% of baseline MAP, or a 45% reduction.
These percent reductions for LLAs are consistent with the recent nested case-
control study of Bijker and colleagues [3], who studied more than 48,000 patients
retrospectively and identified 42 patients with an ischemic strokewithin 10 days of
surgery. These stroke cases were matched by age and type of surgery to 252
controlpatients andadjusted forpotential confounding factors.They founda statis-
tically significant association with the duration that the intraoperative MAP wasBox 3: The lower limit of autoregulation
After reexamination of multiple autoregulation studies, the LLA has been shifted
upward to 70 mm Hg in major texts.
This LLA will not encompass all patients, as there is tremendous interindividual
variability in the LLA. Using a percent reduction from the baseline blood
pressure as a method to estimate the LLA may accommodate this variability.
109CEREBRAL PERFUSION AND AUTOREGULATIONdecreased more than 30% from baseline and the occurrence of an ischemic stroke
within 10 days after surgery [3]; however, half of these 42 patients with stroke had
carotid endarterectomy surgery and 6 had surgery for tumors of the head and
neck. Only 13 cases of stroke occurred after general surgical procedures.
In sharp contrast to the previously mentioned work on the LLA are the
multiple studies from Sharrock and colleagues [40] demonstrating that MAPs
of 50 to 55 mm Hg are well tolerated by patients undergoing hip surgery in
the lateral decubitus position using epidural local anesthetic infusions and intra-
venous epinephrine infusions. Early studies by this group without the epineph-
rine infusions had a ‘‘number of patients’’ with symptoms of cerebral ischemia,
such as yawning, nausea, or drowsiness associated with cardiac indices lower
than 1.8 L/min/m2. When the low-dose epinephrine infusions were added,
cardiac output was increased with a similar MAP, and the symptoms of cere-
bral ischemia abated. These studies imply that cardiac output either directly
or indirectly affects CBF, as CPP reportedly stayed constant.EFFECT OF SIMULTANEOUS FACTORS ON CBF: CLINICAL
SCENARIOS
Patient condition and anesthetic management impose multiple simultaneous
factors that can affect CBF, CMRO2, cerebrovascular reactivity, and autoregu-
lation. Consideration of the underlying vascular tone and the severity of the
physiologic condition and dosage of anesthetic should be made when assessing
adequacy of cerebral perfusion (Box 4). This section provides several examples
of the effects of multiple simultaneous factors on CBF.Effect of carbon dioxide on autoregulation in awake and anesthetized
subjects
Baseline autoregulation studies are typically performed at PaCO2 of approxi-
mately 40 mm Hg, and they demonstrate the range of blood pressure over
which an individual can alter their cerebrovascular tone to maintain a constant
CBF. Because CO2 also alters the vascular tone, at higher PaCO2 levels it will
impose underlying vasodilation and alter the ability of the vasculature to
further dilate with low MAP. Aaslid and colleagues [41] used transcranial
Doppler and insonation of the middle cerebral artery in awake humans to
demonstrate that the fastest rate of regulation of CBF velocity using thigh
cuff deflation occurred with hypocapnia (PaCO2 of 22.2 mm Hg, highest
tone) and the slowest with hypercapnia (PaCO2 of 46.9 mm Hg, lowest tone)
[41]. At even higher PaCO2 levels (50–61 mm Hg) under remifentanil plus sev-
oflurane anesthesia (1.0%–1.1% end tidal concentration), McCulloch and
colleagues [42], using transcranial Doppler, demonstrated that autoregulationBox 4: Underlying vascular tone affects response on CBF
The effect of any drug or change in physiology on the CBF will depend on the
underlying cerebrovascular tone.
110 GREENE & LEEwas significantly impaired in healthy subjects. For propofol (140 lg/kg/min)
anesthesia, the level at which significant impairment of autoregulation occurred
was slightly higher, PaCO2 of 54 to 66 mm Hg. These findings are consistent
with the concept of underlying vascular tone, in this case vasodilation, affecting
the ability of the cerebral vessels to vasoconstrict. Moreover, McCulloch and
colleagues [42] found that CO2 reactivity was greater at an MAP of 100 mm
Hg than at 80 mm Hg, for both sevoflurane and propofol, presumably because
the underlying vasoconstriction at higher MAP allowed the CO2 to exert
a greater effect on vasodilation. At lower MAP with hypercapnia, the ability
to vasodilate fully will be diminished compared with isocapnic conditions,
and the LLA will be shifted to the right, or increased.Effect of hypotension on carbon dioxide reactivity
Harper and Glass [43] demonstrated the effect of varying levels of hypotension
on CO2 reactivity in dogs anesthetized with nitrous oxide and oxygen and
intermittent small doses of thiopentone (Fig. 4). With severe hypotensionFig. 4. The effect of hypotension on CO2 reactivity in dogs. In normothermic (T 38C), normo-
tensive (MAP 150 mm Hg) dogs, the effect of CO2 on CBF was almost linear between PaCO2
20 to 80 mm Hg. The slope of the CO2 reactivity curve decreases with moderate hypotension
(MAP 100 mm Hg). CO2 reactivity is abolished with severe hypotension at a MAP of 50 mm
Hg because of the maximal underlying cerebrovascular dilation caused by the hypotension.
(Adapted from Harper AM, Glass HI. Effect of alterations in the arterial carbon dioxide tension
on the blood flow through the cerebral cortex at normal and low arterial blood pressures. J
Neurol Neurosurg Psychiatry 1965;28:449.)
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Hg), CO2 reactivity is abolished in the dog. The cerebral vasculature is
presumably maximally vasodilated and cannot respond further to increasing
PaCO2. The clinical implication is that during severe hypotension, raising the
PaCO2 level will not necessarily increase CBF.Effect of temperature and propofol dose on CBF and CMRO2
Hypothermia (35C) and increasing propofol doses in monkeys have additive
effects on CMRO2 and CBF reduction (Fig. 5) [44]. No significant interaction
was found between temperature and propofol dose. These findings are consis-
tent with other data suggesting that initial reductions in temperature exert
a greater effect on basal metabolism, whereas anesthetic drugs exert their effect
on functional metabolism. These additive reductions in CMRO2 and CBF,
with good flow-metabolism coupling, may be clinically useful in situations
with elevated ICP.Fig. 5. The additive effects of mild hypothermia and propofol on CBF in dogs. Both propofol
and mild hypothermia (35C) decrease CBF and CMRO2 with good flow-metabolism coupling
in normothermic, isocapnic dogs. The effects are additive (no interaction effect), as mild hypo-
thermia is thought to predominately affect basal metabolism and propofol affects functional
metabolism. *P<.05 comparing normothermic with hypothermic propofol groups. (Adapted
from Ouchi T, Ochiai R, Takeda J, et al. Combined effects of propofol and mild hypothermia
on cerebral metabolism and blood flow in rhesus monkey: a positron emission tomography
study. J Anesth 2006:20:208.)Effect of anemia on CBF and autoregulation
Anemia increases CBF by 2 mechanisms, as discussed previously: reduced
CaO2 and reduced viscosity. Because the cerebral vessels are dilated with
anemia, the LLA is shifted to the right. The ability of the cerebral vessels to
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Maruyama and colleagues [45] demonstrated that increasing severity of anemia
(hematocrit values of 40%, 20%, and 5%) in dogs progressively raises the CBF
at a MAP of 100 mm Hg, such that CBF with a hematocrit of 20% is 1.7-fold
that of baseline hematocrit of 40%, and CBF with a hematocrit of 5% is 3.0-fold
higher than baseline. Additionally, the range of autoregulatory capacity is
progressively diminished with increasing severity of anemia and the LLA is
shifted to the right. The first point of significant CBF reduction in the studies
by Maruyama and colleagues [45], tested at 20–mm Hg increments from MAP
100 to MAP 40 mm Hg, was 40 mm Hg with hematocrit 40%, 60 mm Hg with
hematocrit 20%, and 80 mm Hg with hematocrit 5%. These findings may have
significant clinical implications for patients in the intensive care unit with
stenotic neurovascular lesions or acute neurologic injuries with or without
elevated ICP, where current practice is to avoid transfusion and to tolerate
very low hematocrits.Effect of anemia and hypotension on CBF and O2 delivery
During major surgical procedures with large and rapid blood loss, anemia and
hypotension may coexist. As noted previously, anemia will superimpose under-
lying vasodilation on the cerebral vasculature and increase CBF to provide
stable O2 delivery (DO2). The ability of the vessels to further dilate with hypo-
tension to maintain a constant CBF and DO2 will be diminished. Previous
experiments from our institution using microspheres to measure CBF in nor-
mocapnic, normothermic pigs anesthetized with isoflurane demonstrated this
concept (Fig. 6) [46]. One group of pigs was made hypotensive (euvolemic)
with labetalol (MAP from 73 mm Hg to 52 mm Hg) and maintained stable
CBF and DO2. A separate group of normotensive pigs was made anemic
(hematocrit from 27% to 17% with shed blood and crystalloid replacement
to maintain euvolemia) and increased CBF by approximately 50% from base-
line, resulting in stable DO2. When the conditions of both euvolemic hypoten-
sion and anemia were combined, however, CBF increased by only 8%,
resulting in an approximate 28% decrease in DO2. Because both anemia and
hypotension require cerebral vasodilation to maintain a stable DO2, the
combined effects overwhelmed the capacity of the cerebral vasculature to vaso-
dilate sufficiently, thereby decreasing DO2. Clinical implications are that
patients with severe anemia may not be able to compensate for very low blood
pressure to maintain stable DO2 to the brain. These findings have implications
for limiting the extremes of anemia and hypotension when attempting to mini-
mize blood loss and/or avoid transfusion.ANESTHETIC DRUGS AND VASOACTIVE AGENTS
This section discusses pharmacologic agents available to clinicians to help opti-
mize cerebral perfusion, CMRO2, and brain relaxation in everyday practice.
Because many of the vasoactive drugs are used to lower blood pressure, results
may affected when MAP falls outside of the LLA.
Fig. 6. The effects of anemia and hypotension on CBF and O2 delivery. In normocapnic,
normothermic pigs anesthetized with isoflurane, anemia resulted in a dramatic increase in
CBF, which kept the O2 delivery (DO2) to the brain stable. Similarly, severe hypotension to
a MAP of approximately 50 mm Hg, resulted in stable CBF and stable DO2. When both condi-
tions were combined, the CBF increased only 8%, resulting in a 28% drop in DO2 (*P<.05).
The degree of vasodilation by the cerebral vasculature is limited and may not provide stable
DO2 under extreme physiologic conditions. (Adapted from Lee LA, Deem S, Glenny RW,
et al. Effects of anemia and hypotension on porcine optic nerve blood flow and oxygen
delivery. Anesthesiology 2008;108(5):864.)
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In general, calcium channel blockers (CCBs) exert their effect by inhibiting the
influx of intracellular calcium via voltage-gated calcium channels on the
membrane of the sarcoplasmic reticulum. This inhibition results in less intracel-
lular calcium available, leading to a weaker contraction. CCBs can be divided
into 2 categories based on the presence or absence of a dihydropyridine group.
Dihydropyridine drugs include amlodipine, clevidipine, felodipine, nicardipine,
nifedipine, and nimodipine, whereas nondihydropyridine drugs include diltia-
zem and verapamil. Calcium channels are morphologically distinct in different
types of tissue, including the brain, myocardium, vascular smooth muscle, and
the atrioventricular (AV) conduction system. Thus, there is intraclass vari-
ability with regard to binding selectivity of each calcium channel blocker [47].
Although most of the dihydropyridines exhibit activity in all vascular
smooth muscle, decreasing cardiac afterload and providing a generalized hypo-
tensive effect, nimodipine shows relative selectivity to the cerebral arteries at
clinical doses [48]. It has been shown to provide clinical effectiveness in treating
vasospasm following subarachnoid hemorrhage in humans [49]. Accordingly,
a hypotensive effect is less common with nimodipine, and there is evidence
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other dihydropyridines tend to act mainly in the periphery and have no specific
effect on CBF and cerebral metabolic rate provided mean arterial pressure is
kept constant [51]. Nicardipine is one of the most commonly used intravenous
CCBs in the neurosurgical patient because of its ease of titration. Clevidipine,
approved by the Food and Drug Administration in 2008, is degraded by
plasma esterases with a half-life of approximately 1 minute, compared with ni-
cardipine with a half-life of 4 to 5 hours [52]. Nondihydropyridine CCBs gener-
ally act on the myocardium and the AV conduction system, but also have
a small cerebral vasodilatory effect with increases in CBF, and thus potential
to increase ICP.
CCBs may also block the accumulation of intracellular calcium, which is
involved in intracellular signaling processes in neuronal injury. Unfortunately,
clinical trials have not shown benefit with CCBs, and some experts believe that
more downstream pathways should be targeted [53].NO donors
NO donors represent another class of drugs that can be therapeutically useful
to treat acute episodes of hypertension, but these drugs have their own side
effects that must be considered. All NO donors release NO in the vasculature,
which then activates intracellular guanylate cyclase and increases intracellular
production of cyclic guanosine monophosphate (GMP). Cyclic GMP, in
turn, activates protein kinase G that inactivates myosin light chains causing
smooth muscle relaxation and resultant vasodilation. The cerebral vasodilation
caused by the NO donor drugs can result in significant increases in ICP.
Nitroprusside comes as a salt (sodium nitroprusside [SNP]) and for each
molecule of NO that is released, there remains a potential 5 cyanide ions
that can also be released and cause toxicity within 2 to 3 hours [54]. Studies
on cerebral hemodynamics with SNP show variable results depending on study
conditions but, for the most part, it has little effect on CBF in anesthetized
neurosurgical patients [55]. Larger doses have been associated with loss of au-
toregulation, decreased CBF, and increased ICP. Recognizing the aforemen-
tioned concerns, the exceptionally short half-life of 3 to 4 minutes makes
SNP useful when used on a short-term basis for acute control of blood
pressure.
Nitroglycerin preferentially works as a venodilator and only affects arterial
tone at higher clinical doses in a somewhat unpredictable way. Nitroglycerin
has been shown to vasodilate the major cerebral vessels and to cause a decrease
in CBF velocity but no change in CBF [56]. Other studies have shown
a profound increase in ICP and decrease in CPP with nitroglycerin [57].
Hydralazine, also an NO donor, has its effects mainly at the level of the arte-
rioles with vasodilation. It has similar effects in the brain and the periphery,
causing cerebral vasodilation, increased CBF, and increased ICP.
Adenosine has direct vasodilating effects in the brain, and intravenous infusion
will cause vasodilation of the major cerebral vessels, but no change in CBF [58].
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and is used intraoperatively to transiently stop CBF to facilitate clipping of
cerebral aneurysms.Sympatholytics and sympathomimetics
Whether or not drugs that stimulate or antagonize the body’s intrinsic sympa-
thetic nerve system affect CBF and autoregulation depends on the starting
blood pressure, the clinical dose of the drug given, whether autoregulation is
already impaired, and if the blood brain barrier is open or closed [6]. As
a rule, sympatholytics and sympathomimetics do not have any major direct
effects on CBF outside of their effects on systemic blood pressure, with
a few exceptions that will be discussed in the following paragraphs.
Alpha-1 agonists are frequently used in patients with shock and are
commonly administered to patients undergoing anesthesia. Although there is
potential concern with alpha agonists causing further vasoconstriction leading
to decreased CBF, there is not sufficient evidence to suggest this is the case in
humans. Intracarotid infusion of norepinephrine has been shown to have no
effect on CBF [6], and phenylephrine has been shown not to decrease CBF in-
traoperatively while patients are on cardiopulmonary bypass [59]. At clinical
doses, norepinephrine does carry some beta activity, which gives it different
characteristics with respect to cerebral perfusion than phenylephrine.
Alpha-2 agonists used in clinical practice are clonidine and dexmedetomidine,
the latter of which shows much higher specificity to the alpha-2 adrenoreceptor.
Dexmedetomidine has been shown to decrease CMRO2 and CBF [60,61].
Beta agonists in lower concentrations have few direct effects on the cerebral
vasculature, but in higher doses can increase CMRO2 and CBF [62]. This effect
seems to be pronounced when there is a compromise in the blood brain barrier,
suggesting a direct effect of beta agonists on cerebral metabolic rate [63].
It has become clear that beta-blockers in clinical use today can be thought of
in 2 categories: beta antagonists and beta inverse agonists [64]. Beta agonists
cause an increase in CMRO2, and thus CBF. Beta-blockers demonstrate either
no effect or a reduction in CBF [6]. Esmolol, a fast-acting beta blocker with
a short half-life, has been shown to decrease anesthetic requirements, suggest-
ing it may also decrease CMRO2 and demonstrate some inverse agonist
activity in the brain [65,66].
Dopamine has also been studied extensively and used mainly as a vaso-
pressor in certain disease states, mainly to increase blood pressure in the inten-
sive care setting in septic shock and certain types of cerebral ischemia. The
medical literature currently suggests dopamine works well to increase CBF
in other populations, such as preterm infants who are hypotensive [67] and
patients with TBI [68], although it is not the agent of choice. In general, it
has not demonstrated any direct effects on CBF, but does cause an increase
in the CMRO2 of the choroid plexus and basal ganglia [69,70].
Vasopressin, although not classically considered a part of the sympathetic
nervous system, has mainly been studied in situations of cardiac arrest and
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on CBF.Intravenous anesthetic agents
Most intravenous anesthetic agents, with the exception of ketamine, cause
a reduction in CMRO2 and CBF, exhibiting flow-metabolism coupling. Propo-
fol, barbiturates, and etomidate all directly cause a reduction in CMRO2 by
agonizing c-aminobutyric acid (GABA) sites, with a resultant decrease in
CBF and ICP. Ketamine, an N-methyl-D-aspartate receptor antagonist,
increases CMRO2, CBF, and ICP in awake subjects [71]. When ventilation
is controlled to prevent a rise in PaCO2, and a background anesthetic is also
given, such as a potent volatile anesthetic or a benzodiazepine, there is no
increase in CMRO2, CBF, or ICP.
Benzodiazepines appear also to produce a modest reduction in CBF, but to
a lesser extent than seen with other GABA agonists. This is believed to be
because of a reduction in CMR and a preservation of the coupling of CMR
and CBF [5]. Opioids have shown variable responses in clinical studies and
seem to depend on other anesthetics concomitantly given. In general, the
effects, if present, tend to be mild and may not be clinically significant.Volatile anesthetic agents
Volatile anesthetic agents differ from intravenous anesthetic agents in that they
reduce CMRO2 in a dose-dependent fashion, but increase CBF, particularly at
concentrations greater than 1 minimum alveolar concentration. Halothane has
a far greater effect on CBF than isoflurane, desflurane, or sevoflurane, which all
have similar effects on cerebral vasodilation. NO and xenon vary from the
halogenated anesthetics in their effects on CBF. NO is shown to increase
CBF with a variable effect on CMRO2 [72]. When used as an adjunct to intra-
venous anesthetics, NO causes little change in CBF; however, when it is used
in conjunction with volatile anesthetics, it causes a more dramatic increase in
CBF and ICP [72]. Xenon seems to show a differential effect on CBF on
gray matter and white matter, causing a decrease in the former and increase
in the latter [73].
In general, when considering the pharmacologic effect of a drug on cerebral
perfusion, one must consider the drug’s effects on the cerebral vasculature if
this varies from its effect on the systemic vasculature, the drug’s effect on cere-
bral metabolic rate, the blood pressure before giving the drug, whether or not
administration of the drug will bring the blood pressure outside or inside the
cerebral autoregulatory window, and the patient’s condition with respect to
CBF, CMRO2, and ICP (Box 5).PATIENT DISEASE STATES
Although understanding the complex nature of CBF and autoregulation is
important, it is essential for a clinician to understand how to apply these
concepts to an individual patient, especially when these complex mechanisms
Box 5: Pharmacology key points
 Pharmacologic mechanisms of optimizing cerebral perfusion include altering
systemic arterial pressure, cerebral metabolic rate, and directly acting on cere-
bral arteries and arterioles.
 Drugs that can alter cerebral metabolic rate include not only anesthetics, but
sympatholytics and sympathomimetics, especially when the blood brain barrier
has been compromised.
 When considering an individual drug’s effect on an individual patient, one must
consider the patient’s current condition and what other factors are already
affecting CBF, cerebral metabolic rate, and ICP.
 There is some inconsistency in the medical literature with regard to individual
drug effects on CBF, probably because of lack of control of type of anesthetic,
anemia, etc. several other factors that also influence CBF such as (systemic
MAP, CO2 level, awake versus anesthetized, temperature, type of anesthetic.
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chronic disease, or acute injury (Box 6).Anatomic variants
The most common relevant patient condition is one that will rarely be identi-
fied preoperatively, but can affect a patient’s reserve for tolerating hemody-
namic challenges. The anatomy of the circle of Willis varies widely in
human populations, with estimates showing an intact circle of Willis in as
low as 34% of the population [74–76]. There is evidence suggesting that
patients with an anatomic variant of the classic circle of Willis will have
different perfusion patterns and that some may be at higher risk for ischemia
than others, particularly in the presence of acquired stenotic lesions [77–79].
There is significant evidence in the literature that patients with an incomplete
circle of Willis, to the extent that limits collateral flow, carry a higher lifetime
risk of stroke, particularly in the presence of carotid stenosis. This was best
shown with prospective data from the North American Symptomatic Carotid
Endarterectomy Trial (NASCET) [80], but also with retrospective data
showing a nonfunctional anterior collateral pathway increased the risk ofBox 6: Patient disease state key points
 Subclinical anatomic abnormalities can make patients more susceptible to
ischemic neurologic deficits perioperatively, particularly in the presence of
stenotic vascular lesions.
 Certain disease states, such as hypertension, can shift the normal cerebral au-
toregulation curve to the right.
 TBI can impair normal autoregulation mechanisms making blood pressure
control in these patients paramount to preventing secondary brain injury.
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communicating arteries, the channel that connects the anterior circulation
with the posterior circulation, was associated with border zone infarcts [82],
and the fetal-type circulation has also been associated with higher rates of
stroke in the medical literature with retrospective data [83]. What remains chal-
lenging about treating patients with congenital defects is they are mostly
subclinical until a neurologic insult has occurred.Age effects
There are several common diseases that frequently accompany aging, such as
cerebrovascular disease, cardiovascular disease, and neurologic disease, that
each modify cerebral perfusion and autoregulation in their own way, but
increasing age itself seems to have very little to no effect on dynamic autoregu-
lation [84]. Older patients do have decreased baroreceptor sensitivity and
a change in position could change CBF values significantly, but the autoregu-
lation curve itself seems to be unaffected [85]. There is evidence that static au-
toregulation appears to be affected with increasing age [86]. Elderly patients
also exhibit a wider range of blood pressures diurnally, and elderly patients
may be subject to regional hypoperfusion during certain times of night [87].
Additionally, overall CBF decreases from childhood to middle age, which
may reflect progressive neuronal loss over time [88].
At the other spectrum of age, premature infants are also a vulnerable popu-
lation, as development and maturation of the cerebral vasculature usually is not
complete. In premature infants weighing less than 1500 g, passive CBF is
common, suggesting the autoregulatory mechanisms are still developing and
are not working 20% of the time [89].Chronic hypertension
Patients with chronic hypertension show structural changes in the cerebral
circulation, such as vascular hypertrophy and a shift in the autoregulation
curve to the right producing a higher threshold for the ULA [90]. Studies in
rats provide evidence that these structural changes also provide somewhat of
a protective effect on the HLA and allow chronically hypertensive patients
to tolerate higher blood pressures without causing a hemorrhagic stroke.
Because of these changes, acute hypotension induced with an NO donor,
one of the human body’s intrinsic mechanisms of vasodilation, is not tolerated
as well in these patients and leads to decreased perfusion during hypotension
when compared with normotensive subjects [91]. There is also evidence sug-
gesting there are subclinical regional perfusion abnormalities in the untreated
hypertensive patient [92].
Treating patients with chronic hypertension does provide benefit, as evi-
denced by a decreased rate of ischemic stroke [93,94] and a restoration of
more normal CBF dynamics [95,96]. Acute and chronic care of the chronically
hypertensive patient should be undertaken carefully using the pharmacologic
principles mentioned previously that favor mechanisms causing cerebral vaso-
dilation in addition to peripheral vasodilation.
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have been in adults, a growing prevalence of hypertension in the pediatric pop-
ulation urges the scientific community to examine this population more closely.
It has already been shown that there is an association between hypertension
and altered cerebral hemodynamics in children, potentially causing new prob-
lems in childhood not previously seen [97].Carotid stenosis/occlusion
Carotid artery stenosis is a disease of plaque buildup associated with aging and
hyperlipidemia. One main problem with the disease is that it typically remains
subclinical until it has already progressed into advanced stages. Less
commonly, carotid artery stenosis can develop as a complication of radiation
therapy to the neck [98].
Carotid artery stenosis can lead to regional hypoperfusion if a patient’s anatomy
does not permit adequate collateral flow. According to analysis of the NASCET
data, presence of collateral flow decreases subsequent stroke rate by as much as
60% [99]. Despite collateral flow, there is still a decrease in cerebrovascular reserve
that correlates exponentially with increasing degrees of carotid stenosis [100]. The
vasculature supplied by the affected carotid artery may lose its cerebrovascular
reactivity [101]. Recently, investigators have found that occlusion of the external
carotid artery on the same side may also increase stroke risk [102].
Although there has been much debate about when to surgically intervene
with either a carotid endarterectomy or stenting, it is clear that these proce-
dures can provide overall benefits in selected populations. Key deciding factors
mainly include degree of stenosis and presence of neurologic symptoms. Proce-
dures to alleviate carotid stenosis restore CBF and autoregulatory capacity to
previously hypoperfused vasculature, and may improve some cognitive deficits
induced by carotid artery stenosis [103,104].
There has been immense interest in determining the best course of treatment for
carotid artery stenosis, whether it be placement of a carotid artery stent (CAS) or
carotid endarterectomy (CEA).A randomized controlled trial ofCASversusCEA
(‘‘CREST’’ trial) demonstrated no statistically significant difference in the primary
outcome (determined as combined rates of periprocedural mortality, myocardial
infarction, and stroke, and ipsilateral stroke over 4 years) between the 2 groups;
however, the rate of stroke (4.1% vs 2.3%, P ¼ .012) was higher with CAS,
whereas the rate of myocardial infarction was slightly higher with CEA (1.1%
vs 2.3%, P ¼ .032) [105]. Additionally, outcomes for patients younger than 70
years were better with CAS, and outcomes were better with CEA for patients
older than 70 years orwith symptomatic stenosis. Since publication of theCREST
trial and some meta-analyses following it, the American Heart Association and
American Stroke Association published collaborative recommendations indi-
cating carotid endarterectomy for symptomatic patients and for older patients,
and carotid artery stenting for certain asymptomatic patients of younger age [106].
Cerebral hyperperfusion syndrome (CHS) can occur after a symptom-free
interval postoperatively in 1% to 3% of patients, and is thought to be caused
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that takes time to recover after normal flow is restored [107–109]. It can occur
up to 4 weeks after the original procedure and is associated with a symptomatic
period of nausea, vomiting, headache, or other neurologic deficits. If untreated,
it may lead to ipsilateral hemorrhagic stroke and death in up to 40% of patients
[107]. Methods recently proposed to help prevent this complication, in addition
to strict perioperative blood pressure control, include staged angioplasty, peri-
operative transcranial Doppler measurements, and calculating cerebral circula-
tion time.Traumatic brain injury
TBI is a substantial public health problem with approximately 1.7 million TBIs
every year in the United States [110]. Although the most effective treatment for
this disease is prevention, most medical intervention is focused around prevent-
ing secondary injury, which can affect all systems of the body. Understanding
how cerebral perfusion and autoregulation can be altered in these patients is
paramount to preventing secondary brain injury.
In addition to preventing common sequelae of TBI that negatively affect the
brain, such as hypotension, hypoxia, hypoglycemia, hyperthermia, hypocap-
nia, and intracranial hypertension, the main focus of treatment of TBI is to
continuously deliver oxygen to the brain, which is done by optimizing CPP,
as autoregulation is frequently impaired even with mild head injuries. There
have been several new methods recently published determining methods of
tailoring therapy to each individual patient’s ‘‘ideal perfusion pressure’’ by
analyzing ICP waveforms in addition to arterial pressure waveforms, respira-
tory oscillations, transcranial Doppler, and, in some cases, short-term moderate
hypocapnia [111–113]. In addition, optimizing and measuring neuronal tissue
oxygenation may improve neurologic outcome [114].
In pediatric patients in whom normal CPP values vary widely depending on
age, recent research has focused on the pressure reactivity index to determine
the ideal CPP in children. It is being used to correlate mortality with pressures
below the ideal pressure, and disability with pressures above the ideal pressure
[115]. It may prove to be an important therapeutic target, as low CBF and poor
autoregulatory capacity are highly correlated with poor outcomes [116].EFFECTS OF POSITIONING ON CEREBRAL PERFUSION
Surgery in the beach chair position
A controversial topic surrounding cerebral perfusion that has arisen in the past
several years is anesthetic management of blood pressure in the beach chair
position in patients receiving general anesthesia. This concern arose after
a series of 4 cases was reported in 2005, detailing severe brain damage in the
beach chair position for shoulder surgery [117]. These devastating injuries
were thought to be the result of both surgical requests for deliberate hypoten-
sion and lack of correction of the blood pressure in the sitting position for
height from the noninvasive blood pressure (NIBP) cuff to the external
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always been standard practice in neuroanesthesia, this concept did not effec-
tively transmit into other surgical arenas, particularly one known for relatively
minor outpatient procedures.
Correcting the blood pressure to account for height difference between the
site of measurement and the brain addresses the hydrostatic gradient from
the effect of gravity (Fig. 7). For every centimeter of height difference between
the NIBP cuff and the EAC, 0.77 mm Hg should be subtracted from the NIBP
reading on the arm or leg to approximate the true MAP at the EAC (or for
every inch difference, 2 mm Hg subtracted). It is based on the theory that
the cerebral circulation acts similar to a ‘‘waterfall’’ system subject to gravita-
tional effects, rather than as a closed siphon system that operates independent
of gravity. Since this case series and subsequent controversy, an experiment in
anesthetized giraffes demonstrated that the CBF was controlled by arterial pres-
sure without contribution from a siphon mechanism [118]. Admittedly, the
waterfall concept does not fully explain cerebral circulation in instances of
zero gravity; yet it appears to account for clinically relevant situations.
Many clinical studies have also been performed since this case series was
published, including McCulloch and colleagues’ [119] study showing that
MAP at the EAC decreased 47%  7% in the sitting position at 45 with an
associated 22%  7% decrease in the CBF velocity in the middle cerebral
artery. Systolic blood pressure was 96  10 mm Hg by noninvasive measure-
ment on the arm. Another study, by Jeong and colleagues [120], demonstrated
jugular desaturation to less than 50% for at least 5 minutes in 41% of patients in
the beach chair position under general anesthesia, with a significantly higher
proportion of desaturations in the propofol/remifentanil group (56%) compared
with the sevoflurane/50% NO group (21%, P ¼ .008). Jugular saturation in the
sitting position in the propofol/remifentanil group decreased by 22%  12%
from supine baseline, and by 14%  12% in the sevoflurane/50% NO group.Fig. 7. Beach chair position shown at 45 angle on left, and 70 angle on right. MAP calcu-
lations shown when correcting for the hydrostatic gradient from the site of the noninvasive
blood pressure measurement to the brain.
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at the EAC.
One practice that may further place these patients at risk for cerebral
ischemia is the frequent surgical request for deliberate hypotension, particularly
when it is facilitated with drugs that do not cause cerebral vasodilation. In addi-
tion to the need to correct for the hydrostatic gradient in these cases, we previ-
ously discussed how hypotension caused by low cardiac output (ie,
hemorrhage, or in this situation head up position under general anesthesia)
has been shown to raise the LLA compared with hypotension induced by vaso-
active agents. Other issues that may predispose to inadequate cerebral perfu-
sion are the wide variability in the LLA among individuals, the very high
incidence of incomplete circle of Willis anatomy in the general population,
specialized headrests and head positions that may distort the vascular anatomy
in the head and neck, and previously asymptomatic stenotic vascular lesions.
Despite having the ‘‘deck’’ stacked against adequate cerebral perfusion in these
procedures, the incidence of these devastating injuries appears to be low,
although no reliable mechanism for reporting exists. These procedures are typi-
cally brief, lasting only a few hours; yet, one professional liability company
recently noted at least 9 lawsuits associated with neurological injuries sustained
in the beach chair position with large settlement payments related to the issue
of hypotension and uncorrected blood pressure in the sitting position [121].Venous effect on CPP: ischemic optic neuropathy associated with
prolonged prone or steep trendelenburg position
Since the late 1990s, the perioperative complication of ischemic optic neurop-
athy after prolonged prone spine surgery has received significant attention
from anesthesiologists, spine surgeons, and neuro-ophthalmologists. In early
2012, a multicenter case-control study using 80 cases of ischemic optic neurop-
athy (ION) from the American Society of Anesthesiologists Postoperative
Visual Loss Registry and comparing them with 315 controls from 17 centers
across North America identified 6 independent risk factors for ION after prone
spine surgery [122]. These 6 risk factors are male sex, obesity, use of a Wilson
frame, prolonged duration of anesthesia (ie, surgery), increased blood loss, and
decreased administration of colloid in the nonblood fluid administration. With
the exception of male sex, these risk factors all support the theory that this
complication is related to elevated venous pressure in the prone position
with subsequent interstitial fluid accumulation and compromise of the vascular
supply to the optic nerve. Although no animal data have yet supported this
theoretical pathophysiologic mechanism, its occurrence in these 2 procedures
with greatly elevated venous pressure, and in bilateral radical head and neck
operations is consistent with this theory. This complication is unique because
it highlights the importance of outflow pressure in CPP in non-neurosurgical
procedures. Whether or not increasing the MAP in these cases is beneficial has
not been tested, as it is not clear that using excessive inflow pressure will improve
perfusion once the venous outflow problem has developed. Interestingly, these
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liable intraoperative monitor for detecting optic nerve ischemia or dysfunction
intraoperatively during general anesthesia.
INTRAOPERATIVE MONITORS FOR ASSESSMENT OF CBF AND
CEREBRAL ISCHEMIA
For the general anesthesiologist, use of equipment such as a transcranial
Doppler, although useful, is not practical, and can require significant setup
time. For high-risk cases, such as CEA, its benefit may be enormous, and ob-
taining a vascular technologist to measure CBF velocity intraoperatively is rec-
ommended when available. Similarly, 16-channel EEG is not likely to be used
on an outpatient procedure, but may prove valuable in high-risk procedures.
Alternatively, the widespread use of the bispectral index, which is a processed
EEG, can provide crude assessments of frontal brain activity, and may give
some indication of global adequacy of perfusion. Near infrared spectroscopy
is currently widely used in research, but its reliance on trends and lack of
absolute values for ischemia make its validity unclear, particularly in adults
in whom skull thickness is much greater than in neonates. For anesthesio-
logists who work at major neurosurgical or neurotrauma centers, familiarity
with ICP monitors is essential, and use of surgically placed brain tissue
oxygen monitors and autoregulation testing may also be useful for guiding
anesthetic management. The expansion of intraoperative evoked potential mo-
nitoring to detect cerebral ischemia, as well as injury to the spinal cord and
peripheral nerves, may significantly alter anesthetic management, and can
provide early warnings of injury and allow modification of surgical and anes-
thetic care.
The concepts discussed in this updated review should help anesthesiologists
optimize management of cerebral perfusion in routine outpatient and inpatient
procedures, high-risk neurosurgical and non-neurosurgical procedures, and in
high-risk patients with preexisting cerebrovascular disease.References
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